Tyra Biosciences, Inc. Selling, General and Administrative Expense
Tyra Biosciences, Inc. (TYRA) reported Selling, General and Administrative Expense of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2023-11-07
- Tyra Biosciences, Inc. selling, general and administrative expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Tyra Biosciences, Inc. selling, general and administrative expense for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Tyra Biosciences, Inc. selling, general and administrative expense for the quarter ending 2022-09-30 was $173.00K.
- Tyra Biosciences, Inc. selling, general and administrative expense for the quarter ending 2022-06-30 was $186.00K.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month |
|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |
| 2022-09-30 | $173.00K 10-Q · filed 2023-11-07 | $359.00K derived: sum of 2 quarters · filed 2023-11-07 | $570.00K 10-Q · filed 2023-11-07 |
| 2022-06-30 | $186.00K 10-Q · filed 2023-08-10 | $396.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |